Ex­clu­sive: Gary Glick’s Odyssey rais­es $101M Se­ries C as first im­munol­o­gy drugs ap­proach the clin­ic

Odyssey Ther­a­peu­tics has raised $101 mil­lion in a new round, as the Boston biotech pre­pares for its first drug can­di­dates to soon en­ter the clin­ic, CEO Gary Glick told End­points News.

Glick is a chem­istry pro­fes­sor turned se­r­i­al en­tre­pre­neur who found­ed Lyc­era, IFM Ther­a­peu­tics, and Scor­pi­on Ther­a­peu­tics. He’s helped dis­cov­er six pro­grams that have reached the clin­ic, with three or four still pro­gress­ing, he said. But bring­ing a drug through ap­proval is “one of the pin­na­cle sci­en­tif­ic chal­lenges” that he hopes to achieve with Odyssey. And in just two years, the com­pa­ny has raised near­ly half a bil­lion dol­lars to de­vel­op a suite of drugs in im­munol­o­gy and on­col­o­gy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER